Role of transporters in the distribution of platinum-based drugs

被引:79
作者
Harrach, Saliha [1 ]
Ciarimboli, Giuliano [1 ,2 ]
机构
[1] Univ Munster, Univ Hosp Munster, Med Clin D, Expt Nephrol, D-48149 Munster, Germany
[2] Univ Munster, Univ Hosp Munster, Interdisciplinary Ctr Clin Res IZKF, D-48149 Munster, Germany
来源
FRONTIERS IN PHARMACOLOGY | 2015年 / 6卷
关键词
cisplatin; oxaliplatin; transporters; side effects; uptake; ORGANIC CATION TRANSPORTERS; CISPLATIN-INDUCED NEPHROTOXICITY; ADENOSINE-TRIPHOSPHATASE ATP7B; CELLULAR PHARMACOLOGY; COPPER TRANSPORTERS; OXALIPLATIN; RESISTANCE; CARBOPLATIN; TOXICITY; CTR1;
D O I
10.3389/fphar.2015.00085
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Platinum derivatives used as chemotherapeutic drugs such as cisplatin and oxaliplatin have a potent antitumor activity. However, severe side effects such as nephro-, oto-, and neurotoxicity are associated with their use. Effects and side effects of platinum-based drugs are in part caused by their transporter-mediated uptake in target and non target cells. In this mini review, the transport systems involved in cellular handling of platinum derivatives are illustrated, focusing on transporters for cisplatin. The copper transporter 1 seems to be of particular importance for cisplatin uptake in tumor cells, while the organic cation transporter (OCT) 2, due to its specific organ distribution, may play a major role in the development of undesired cisplatin side effects. In polarized cells, e.g., in renal proximal tubule cells, apically expressed transporters, such as multidrug and toxin extrusion protein 1, mediate secretion of cisplatin and in this way contribute to the control of its toxic effects. Specific inhibition of cisplatin uptake transporters such as the OCTs may be an attractive therapeutic option to reduce its toxicity, without impairing its antitumor efficacy.
引用
收藏
页数:7
相关论文
共 94 条
[1]   The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons [J].
Adelsberger, H ;
Quasthoff, S ;
Grosskreutz, J ;
Lepier, A ;
Eckel, F ;
Lersch, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 406 (01) :25-32
[2]   Interventions for preventing neuropathy caused by cisplatin and related compounds [J].
Albers, James W. ;
Chaudhry, Vinay ;
Cavaletti, Guido ;
Donehower, Ross C. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (02)
[3]  
Amptoulach Sousana, 2011, Chemother Res Pract, V2011, P843019, DOI 10.1155/2011/843019
[4]   Copper Transporter 2 Regulates Endocytosis and Controls Tumor Growth and Sensitivity to Cisplatin In Vivo [J].
Blair, Brian G. ;
Larson, Christopher A. ;
Adams, Preston L. ;
Abada, Paolo B. ;
Pesce, Catherine E. ;
Safaei, Roohangiz ;
Howell, Stephen B. .
MOLECULAR PHARMACOLOGY, 2011, 79 (01) :157-166
[5]   Copper Transporter 2 Regulates the Cellular Accumulation and Cytotoxicity of Cisplatin and Carboplatin [J].
Blair, Brian G. ;
Larson, ChristopherA. ;
Safaei, Roohangiz ;
Howell, Stephen B. .
CLINICAL CANCER RESEARCH, 2009, 15 (13) :4312-4321
[6]  
BREGMAN CL, 1986, CANCER CHEMOTH PHARM, V18, P117
[7]   Neuronopathy due to cisplatinum [J].
Cano, JR ;
Catalan, B ;
Jara, C .
REVISTA DE NEUROLOGIA, 1998, 27 (158) :606-610
[8]  
Carozzi VA, 2010, CURR CANCER DRUG TAR, V10, P670
[9]   Oxaliplatin-related side effects: Characteristics and management [J].
Cassidy, J ;
Misset, JL .
SEMINARS IN ONCOLOGY, 2002, 29 (05) :11-20
[10]   Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity [J].
Cavaletti, G ;
Zanna, C .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (14) :1832-1837